Rezolute (NASDAQ:RZLT) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Rezolute (NASDAQ:RZLT) posted its earnings results on Thursday. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14), Zacks reports.

Rezolute Trading Up 5.4 %

NASDAQ RZLT traded up $0.26 during midday trading on Friday, hitting $5.08. The company had a trading volume of 1,514,825 shares, compared to its average volume of 440,479. The firm has a 50-day moving average price of $4.62 and a 200-day moving average price of $3.72. The company has a market capitalization of $203.89 million, a PE ratio of -4.46 and a beta of 1.18. Rezolute has a twelve month low of $0.72 and a twelve month high of $6.10.

Analysts Set New Price Targets

RZLT has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a report on Monday, September 9th. Maxim Group upped their price target on shares of Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. JMP Securities restated a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a research report on Friday. Craig Hallum initiated coverage on Rezolute in a research report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Guggenheim began coverage on Rezolute in a research note on Tuesday, August 27th. They set a “buy” rating and a $11.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $11.57.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.